儿童口服缓控释制剂研究进展  

Research Progress on Oral Sustained and Controlled Release Pediatric Formulations

作　　者：王瑞丽 赵立波 张晓燕 WANG Ruili;ZHAO Libo;ZHANG Xiaoyan(Clinical Research Center,Beijing Children’s Hospital,Capital Medical University,Beijing 100045,China;School of Pharmaceutical Sciences,Capital Medical University,Beijing 100069,China)

机构地区：[1]首都医科大学附属北京儿童医院临床研究中心,北京100045 [2]首都医科大学药学院,北京100069

出　　处：《中国现代应用药学》2020年第13期1661-1664,共4页Chinese Journal of Modern Applied Pharmacy

基　　金：“重大新药创制”国家科技重大专项(2018ZX09721-003)。

摘　　要：口服缓控释制剂可减少给药次数、提高患者依从性、减少不良反应发生率,与特定年龄儿童的需求相匹配,是目前药物剂型研发的热点。本文通过调研国内外口服缓控释制剂发展现状及儿童可用的上市口服缓释制剂药品品种情况,对儿童口服缓控释制剂发展现状进行阐述和总结,以期为中国儿童用药研发和应用提供参考意见。Oral sustained and controlled release formulations can reduce the dose frequency,improve patients’compliance,reduce the incidence of adverse reactions and can also match some specific needs for children at a certain age,which is developed into a hot research area now.After reviewing the development of oral sustained and controlled release formulations at home and abroad and collecting the available varieties of oral sustained and controlled release formulations for children,this article elaborate and summarize development of oral sustained and controlled release formulations so as to provide some advice for the development and application of medicine for children in China.

关 键 词：儿童 口服缓控释制剂 不良反应 

分 类 号：R94[医药卫生—药剂学]